 Health Care |
Health Care |
|
|
Sanders gets soundbites, few answers from pharma CEOs |
Drug company CEOs were in the hot seat Thursday as Sen. Bernie Sanders (I-Vt) sought to harness the anger over high drug prices into action. |
© Allison Robbert, The Hill |
During the Senate Health, Education Labor and Pensions (HELP) Committee hearing, Sanders pressed the CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb about why their medicines cost so much more in the U.S. compared to other countries.
"The overwhelming beneficiary of high drug prices in America is the pharmaceutical industry," Sanders said Thursday. "The United States government does not regulate drug companies. With a few exceptions, the drug companies regulate the United States government."
The Vermont senator has long criticized pharma companies for their pricing tactics, and in a similar hearing last year extracted a promise of no insulin price hikes from the CEO of Eli Lilly. In another hearing, the CEO of Moderna pledged that nobody would have to pay out pocket for the company's COVID-19 shot.
But he received no such guarantees from any of the executives testifying Thursday, and the panel's top Republican said Sanders was wasting people's time with a show trial.
"I wish this were a genuine exercise. I am willing to do the work, my colleagues are too," Sen. Bill Cassidy (R-La.) said. "This committee has devolved into CEO whack-a-mole with little to show."
The CEOs largely stuck to familiar talking points and blamed the U.S. health system — namely third-party pharmacy benefit managers (PBMs) — for the substantial differences in list prices.
Larry Levitt, executive vice president for health policy at the research group KFF, said nobody should have realistically expected the CEOs to promise anything.
"I would not expect the CEO of a drug company to stand before Congress and just all of a sudden give up millions of dollars in revenues and profits by committing to lowering prices," Levitt said, adding the promises from Lilly and Moderna were much narrower in scope than what Sanders was asking Thursday.
The executives acknowledged that list prices have increased, but they countered that revenues have not, and more money is going toward paying rebates to PBMs.
The CEOs admitted their companies were still making profits selling their drugs abroad despite the much lower prices, but all three said patient access to drugs in the U.S. is much easier than in other countries.
"Those drugs mean nothing to anybody who cannot afford it," Sanders countered. |
Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel and Joseph Choi — every week we follow the latest moves on how Washington impacts your health. |
|
|
How policy will be impacting the health care sector this week and beyond: |
|
|
Missouri senators voted Wednesday against amendments that would have allowed abortions in the cases of rape and incest in the state. Missouri senators debated a bill that would make it illegal for public funds to go toward abortion providers, such as Planned Parenthood. During the debate, Missouri state Sen. Tracy McCreery (D) introduced amendments that would allow exceptions for abortion in incest and rape cases. "I think … |
| |
|
LEESBURG, Va. — House Democratic leaders are vowing to make abortion their top issue on the campaign trail this year, betting that Republican efforts to roll back women's reproductive rights will drive voters to the polls to the distinct advantage of President Biden and his allies in Congress. Gathered in Northern Virginia for their annual strategy retreat, the Democrats are hearing from experts — and honing their message — … |
| |
|
Former chief White House medical adviser Anthony Fauci plans to release a memoir in June, reflecting on his long career as an infectious disease expert who served in multiple administrations. Book publisher Viking announced Thursday the release of "On Call: A Doctor's Journey in Public Service." The 496-page book will be published June 18. Fauci served under seven presidents, beginning in the Reagan administration. He … |
| |
|
A MESSAGE FROM KIDNEY CARE ACCESS COALITION |
Dialysis patients and their families are being harmed. |
A new bipartisan bill will restore essential protections – for patients and their families. Congress: pass H.R. 6860, the bipartisan Restore Protections for Dialysis Patients Act. Learn more |
|
|
Branch out with a different read from The Hill: |
|
|
Higher-dose naloxone spray didn't save more lives, researchers find |
NEW YORK (AP) — A new, higher-dose nasal spray for reversing opioid overdoses did not save more lives than the previous standard dose, but it did cause more vomiting and other side effects, researchers wrote in a study published Thursday. The 8-milligram naloxone spray — twice as potent as the highest dose previously available — was approved … |
|
|
Local and state headlines on health care: |
- Legislation trying to tweak Ohio's new adult-use marijuana law continues to be at a standstill (Ohio Capital Journal)
- California wants to cap your medical bills. Guess who's pushing back. (Cal Matters)
- As another rural Kansas clinic shutters, Kelly renews call for Medicaid expansion (Kansas Reflector)
|
|
|
Health news we've flagged from other outlets: |
- House approves ban on disputed measure for valuing treatments (Axios)
- Lawmakers' retirements risk leaving doctor pay fix unfinished (Roll Call)
- FDA's plan to ban hair relaxer chemical called too little, too late (KFF Health News)
|
|
|
Most read stories on The Hill right now: |
|
|
Retired federal Judge J. Michael Luttig said Thursday the Supreme Court has no "legitimate off-ramps" to avoid a decision on whether former President … Read more |
| The Supreme Court heard oral arguments Thursday about whether former President Trump could be banned from the ballot this year. The case stems from … Read more |
|
|
Opinion related to health submitted to The Hill: |
|
|
You're all caught up. See you tomorrow! |
1625 K Street NW, 9th Floor, Washington, DC 20006 |
Copyright © 1998 - 2024 Nexstar Media Inc. | All Rights Reserved. |
|
|
|
If you believe this has been sent to you in error, please safely unsubscribe.
No comments:
Post a Comment